Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak Webcast scheduled for 7:00 PM ET / 4:00 PM PT to discuss IBS-C Market WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update o ...